Answers are grounded in this paper and cite their sources.
Prospective cohort study shows viral clearance is faster for influenza than SARS-CoV-2 among immunocompromised patients, indicating significant differences in shedding kinetics.
There are limited data comparing viral shedding between influenza and SARS-CoV-2 in immunocompromised patients. We prospectively enrolled 70 SARS-CoV-2 and 16 influenza patients, with 48 SARS-CoV-2 patients matched to 16 influenza patients by propensity score. Weekly-collected respiratory samples were subjected to viral culture and antigen testing. In matched cohorts, the time to culture-confirmed viral clearance was shorter for influenza than SARS-CoV-2 (median, 4.5 vs. 29 days; adjusted Hazard Ratio [aHR] 27.5; P <0.001), and antigen negativity occurred faster (3 vs. 23 days; aHR 19.2; P <0.001). These findings show different clearance kinetics for influenza and SARS-CoV-2 in immunocompromised patients.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: